新型促甲状腺激素免疫球蛋白检测在Graves病与甲状腺眼病中的诊断价值
该横断面研究纳入110人,分5组,比较两种临床可用TSH受体抗体检测(ROC-TBII与QUI-TSI)与新型水母发光蛋白TSAb检测(OTS-TSI)。OTS-TSI区分Graves病与甲状腺炎敏感性100%、特异性100%,与QUI-TSI相同但优于ROC-TBII;诊断甲状腺眼病敏感性93%、特异性100%,优于QUI-TSI和ROC-TBII。
要点
- OTS-TSI区分Graves病与甲状腺炎敏感性100%、特异性100%,优于ROC-TBII。
- OTS-TSI诊断甲状腺眼病敏感性93%、特异性100%,优于QUI-TSI和ROC-TBII。
- OTS-TSI检测范围20-29,000 mIU/L,周转时间≤6小时,无需细胞培养设备。
核心结论
- OTS-TSI在Graves病与甲状腺炎鉴别诊断中表现优异,与QUI-TSI相当但优于ROC-TBII。
- OTS-TSI诊断甲状腺眼病敏感性优于QUI-TSI和ROC-TBII,同时保持高特异性。
- OTS-TSI周转时间短且无需细胞培养和无菌设备。
研究设计与样本
- 横断面研究,在治疗开始前采集数据,纳入110人分5组。
- 队列1为初发或复发Graves病36例,队列2为无痛性或亚急性甲状腺炎17例。
- 队列3为Graves眼病/甲状腺眼病27例,队列4为桥本甲状腺炎10例,队列5为正常志愿者20例。
- 比较Roche Elecsys anti-TSHR检测(ROC-TBII)、Thyretain TSI Reporter BioAssay Kit(QUI-TSI)与Otsuka水母发光蛋白TSAb检测(OTS-TSI)。
主要发现
- OTS-TSI区分Graves病与甲状腺炎敏感性100%、特异性100%,与QUI-TSI相同,优于ROC-TBII(敏感性86%、特异性94.1%)。
- OTS-TSI诊断甲状腺眼病对比正常对照敏感性93%、特异性100%。
- QUI-TSI和ROC-TBII诊断甲状腺眼病表现相似,敏感性82%、特异性100%。
- OTS-TSI可检测值范围20-29,000 mIU/L,周转时间≤6小时。
关键数值与推荐
- OTS-TSI区分Graves病与甲状腺炎:敏感性100%、特异性100%。
- ROC-TBII区分Graves病与甲状腺炎:敏感性86%、特异性94.1%。
- OTS-TSI诊断甲状腺眼病:敏感性93%、特异性100%。
- QUI-TSI和ROC-TBII诊断甲状腺眼病:敏感性82%、特异性100%。
- OTS-TSI检测范围20-29,000 mIU/L,周转时间≤6小时。
临床怎么用
- OTS-TSI可用于Graves病与甲状腺炎的鉴别诊断,性能与QUI-TSI相当且优于ROC-TBII。
- OTS-TSI对甲状腺眼病诊断敏感性更高,适合需要快速结果且无细胞培养条件的实验室。
- 临床选择TSAb检测时应考虑敏感性、周转时间和设备要求。
局限性
- 研究为横断面设计,样本量110人,各队列例数较少。
- 结论需在美国人群中进行更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The syndrome of thyrotoxicosis typically relies on radioactive iodine scans for establishing its etiology. Alternatively, the determination of thyrotropin (TSH) receptor antibodies (TRAbs) helps to distinguish Graves' disease (GD) from thyrotoxic thyroiditis. Current assays are impacted by limitations in sensitivity and/or turnaround time. Therefore, we decided to test a new assay for the detection of TSH receptor stimulating antibodies (TSAbs) and compare it with the clinically available assays. Methods: We enrolled 110 individuals in 5 cohorts: patients with incident or recurrent GD (cohort 1); patients with thyroiditis, painless or subacute (cohort 2); patients with Graves' orbitopathy/thyroid eye disease (TED) in cohort 3; patients with Hashimoto's thyroiditis (cohort 4), and a control group of normal volunteers (cohort 5). The patients were tested with the two clinically available assays: Roche Elecsys anti-TSHR assay (ROC-TBII) from Roche Diagnostics and Thyretain™ TSI Reporter BioAssay Kit (QUI-TSI) from Quidel. In addition, the samples were tested with the aequorin TSAb assay (OTS-TSI) provided by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). The data were collected in a cross-sectional manner before initiation of therapy. Results: We had 36 cases of GD, 17 cases of thyroiditis, 27 cases of TED, 10 cases of Hashimoto's thyroiditis, and 20 normal volunteers. OTS-TSI had 100% sensitivity and specificity in distinguishing GD from thyroiditis, identical with QUI-TSI but superior to ROC-TBII (sensitivity 86% and specificity 94.1%). OTS-TSI had 93% sensitivity and 100% specificity for the diagnosis of TED, compared with normal controls. QUI-TSI and ROC-TBII performed similarly in this analysis, demonstrating 82% sensitivity and 100% specificity. The range of detectable values for OTS-TSI was 20-29,000 mIU/L and the turnaround time was ≤6 hours, without the need for cell culture equipment. Conclusions: OTS-TSI performed excellently, though similarly to QUI-TSI, for the differential diagnosis of GD vs. thyroiditis, while being superior in that respect to ROC-TBII. Furthermore, OTS-TSI has superior sensitivity to QUI-TSI and ROC-TBII for TED diagnosis, while retaining high specificity. It has a short turnaround time and avoids the need for cell culture and sterility. Larger studies in U.S. populations are needed for its validation.
引用
- Stan MN, Algeciras-Schimnich A, Murthy V, et al. Diagnostic Utility of a New Assay for Thyroid Stimulating Immunoglobulins in Graves' Disease and Thyroid Eye Disease. Thyroid. 2021. PMID: 34714163. doi:10.1089/thy.2021.0299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。